EUVIMEDEUVIMED entdecken
Crossref

DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma

Lu Yang, Yanlong Feng, Xuewen Liu, Qin Zhang, Yaqin Liu, Xing Zhang, Ping Li, Dongsheng Chen

Investigational New Drugs · 2025

DOI: 10.1007/s10637-024-01495-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Investigational New Drugs, 2025. Verfasst von Lu Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Science and Technology, Nanjing Forestry University, Nanjing, 210037, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dynein cytoplasmic 2 heavy chain 1 (DYNC2H1) is reported to play a potential role in cancer immunotherapy. However, the association between DYNC2H1 mutation and the clinical benefit of immunotherapy in non-small cell lung cancer (NSCLC) and melanoma remains to be elucidated. We collected data from three public immune checkpoint inhibitor (ICI)-treated NSCLC cohorts (n = 137 in total) and seven ICI-treated melanoma cohorts (n = 418 in total) to explore the potential of DYNC2H1 mutation as a predictive biomarker. The clinical outcomes, including the objective response rate (ORR) and progression-free survival (PFS), of patients with DYNC2H1 mutations are significantly better than those of patients with wild-type DYNC2H1. Multivariate Cox regression analysis confirmed that DYNC2H1 mutation was an independent predictive factor for ICI efficacy in NSCLC and melanoma. In addition, DYNC2H1 mutation exhibited no prognostic value for NSCLC or melanoma. Tumour mutational burden (TMB) and tumour neoantigen burden (TNB) were significantly higher in patients with DYNC2H1 mutation than in those with wild-type DYNC2H1 in both NSCLC and melanoma cohort. The analysis of immune-related genes and immune cell enrichment revealed an association between DYNC2H1 mutation and increased immune infiltration, revealing a potential mechanism underlying the predictive role of DYNC2H1 mutation in immunotherapy efficacy. In conclusion, DYNC2H1 mutation serves as a predictive biomarker of ICI efficacy in NSCLC and melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMelanomaImmune Checkpoint InhibitorsBiomarkers, TumorCytoplasmic DyneinsHumansMutationMaleFemaleMiddle AgedAgedAdultPrognosis

Stichwörter der Autor:innen

DYNC2H1 mutationBiomarkerICI treatment efficacyMelanomaNSCLC

Substanzen

Immune Checkpoint InhibitorsBiomarkers, TumorCytoplasmic Dyneins

Autor:innen und Institutionen

  • Department of Science and Technology, Nanjing Forestry University, Nanjing, 210037, China.
  • Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
  • The State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, 210002, China.
  • Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. tzliping@163.com.
  • The State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, 210002, China. dongsheng.chen@simceredx.com.
  • Cancer Center, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, 121001, China. dongsheng.chen@simceredx.com.

Zitieren

APA

Yang, L., Feng, Y., Liu, X., Zhang, Q., Liu, Y., Zhang, X., Li, P., & Chen, D. (2025). DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01495-3

Vancouver

Yang L, Feng Y, Liu X, Zhang Q, Liu Y, Zhang X, et al. DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma. Investigational New Drugs. 2025. doi:10.1007/s10637-024-01495-3

BibTeX
@article{Yang2025,
  author = {Yang, Lu and Feng, Yanlong and Liu, Xuewen and Zhang, Qin and Liu, Yaqin and Zhang, Xing and Li, Ping and Chen, Dongsheng},
  title = {DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma},
  journal = {Investigational New Drugs},
  year = {2025},
  doi = {10.1007/s10637-024-01495-3}
}
Kostenlos starten →